Wehrenberg-Klee Eric, Goyal Lipika, Dugan Matthew, Zhu Andrew X, Ganguli Suvranu
Department of Radiology, Massachusetts General Hospital, Boston, MA, USA.
Massachusetts General Hospital Cancer Center, Boston, MA, USA.
Cardiovasc Intervent Radiol. 2018 Nov;41(11):1799-1802. doi: 10.1007/s00270-018-1993-1. Epub 2018 May 29.
Nivolumab has recently received approval by the Food and Drug Administration for treatment of advanced hepatocellular carcinoma (HCC) in patients previously treated with sorafenib. Nivolumabs' overall response rate of 20% (El-Khoueiry et al. in Lancet 389:2492-2502, 2017) is a step forward for these patients, but there is significant room for improvement. We describe a case of combining Y-90 radioembolization with nivolumab for treatment of angioinvasive HCC, which successfully bridged patient to partial hepatectomy. Surgical pathology showed negative margins with complete pathological response. With the introduction of immunotherapy for HCC, combining Y-90 radioembolization with immunotherapy may enhance the anti-tumoral immune response of checkpoint inhibitors.
纳武单抗最近已获得美国食品药品监督管理局的批准，用于治疗先前接受过索拉非尼治疗的晚期肝细胞癌（HCC）患者。纳武单抗20%的总体缓解率（El-Khoueiry等人，《柳叶刀》389:2492 - 2502，2017）对于这些患者来说是向前迈进了一步，但仍有很大的改进空间。我们描述了一例将Y-90放射性栓塞与纳武单抗联合用于治疗血管侵袭性HCC的病例，该病例成功使患者过渡到部分肝切除术。手术病理显示切缘阴性且有完全病理缓解。随着HCC免疫疗法的引入，将Y-90放射性栓塞与免疫疗法相结合可能会增强检查点抑制剂的抗肿瘤免疫反应。
